180 related articles for article (PubMed ID: 16023163)
1. Use of in vitro methods to predict QT prolongation.
Hammond TG; Pollard CE
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):446-50. PubMed ID: 16023163
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
3. [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals].
Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):377-83. PubMed ID: 12835531
[TBL] [Abstract][Full Text] [Related]
4. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
5. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
Lee N; Authier S; Pugsley MK; Curtis MJ
Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
[TBL] [Abstract][Full Text] [Related]
6. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.
Dumotier BM; Georgieva AV
Cell Biol Toxicol; 2007 Jul; 23(4):293-302. PubMed ID: 17216548
[TBL] [Abstract][Full Text] [Related]
7. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
9. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
10. Prolong QT interval and "torsades de pointes" associated with different group of drugs.
Gongadze N; Kezeli T; Antelava N
Georgian Med News; 2007 Dec; (153):45-9. PubMed ID: 18250496
[TBL] [Abstract][Full Text] [Related]
11. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Gintant G
Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
[TBL] [Abstract][Full Text] [Related]
13. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
Hondeghem LM
J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
15. The preclinical assessment of the risk for QT interval prolongation.
Champeroux P; Martel E; Vannier C; Blanc V; Leguennec JY; Fowler J; Richard S
Therapie; 2000; 55(1):101-9. PubMed ID: 10860008
[TBL] [Abstract][Full Text] [Related]
16. The impact of drug-induced QT interval prolongation on drug discovery and development.
Fermini B; Fossa AA
Nat Rev Drug Discov; 2003 Jun; 2(6):439-47. PubMed ID: 12776219
[TBL] [Abstract][Full Text] [Related]
17. Assessment of QT liabilities in drug development.
Arrigoni C; Crivori P
Cell Biol Toxicol; 2007 Jan; 23(1):1-13. PubMed ID: 17013551
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
Darpo B; Nebout T; Sager PT
J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
[TBL] [Abstract][Full Text] [Related]
19. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
20. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]